替雷利珠单抗联合PC方案治疗晚期肺癌的疗效及对血清PI3K、Akt的影响.

OBJECTIVE: To probe into the effects of tislelizumab combined with PC regimen (pemetrexed + cisplatin) in the treatment of advanced lung cancer. METHODS: Totally 82 patients with advanced lung cancer in the hospital from Feb. 2021 to Feb. 2022 were extracted to be divided into the observation group (n =41) and the control group (n = 41) via the random number table method. The control group was treated with PC regimen, while the observation group received tislelizumab on the basis of the control group. The disease remission rate and adverse reactions were compared between two groups. Before treatment, after 2 cycles of treatment and after 4 cycles of treatment, the levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and cytokeratin 19 fragment (CYFRA21-1), T lymphocytes, serum phosphatidylinositol-3 kinase (PI3K) and protein kinase B (Akt) were compared between two groups. RESULTS: The disease remission rate of 56. 10% (23/41) in the observation group was higher than that of 34. 15% (14/41) in the control group, with statistically significant difference (P < 0. 05). After 2 cycles of treatment and after 4 cycles of treatment, the serum levels of CEA, CA125, CYFRA21-1, PI3K and Akt in two groups were lower than those before treatment, and after 4 cycles of treatment were lower than after 2 cycles of treatment, and the observation group were lower than the control group, with statistically significant differences (P<0. 05). After 2 cycles of treatment and after 4 cycles of treatment, the levels of CD3+, CD4+, CD4+ / CD8+ in the observation group were higher than those before treatment and higher than those in the control group, with statistically significant differences (P<0. 05). There was no significant difference in the incidence of adverse reactions between two groups (P >0. 05). CONCLUSIONS: The efficacy of tislelizumab combined with PC regimen in the treatment of advanced lung cancer is significant, which can reduce the level of tumor markers, inhibit the PI3K/ Akt signaling pathway and enhance immune function with higher safety. [ABSTRACT FROM AUTHOR]